Talha Burki speaks with Fred Ramsdell, Mary Brunkow, and Shimon Sakaguchi about their Nobel-winning discoveries in peripheral ...
Sana Biotechnology, Inc. is a Strong Buy with promising cell therapies for diabetes & B-cell disorders. Click here to find ...
A research team has introduced a novel cancer immunotherapy strategy. This approach involves attaching "fake targets" to tumor cells to guide immune cell attacks, overcoming the limitations of ...
Samer A. Srour, MB ChB, MS, has long hoped the remarkable success of chimeric antigen receptor therapy for treatment of hematologic malignancies could be replicated in other cancer types.“There is a ...
Researchers at the Medical University of Vienna have taken a closer look at a previously largely unknown component of the immune system: the protein molecule TRAT1 (T Cell Receptor Associated ...
T-cell engagers, especially BiTEs, show promise in treating solid tumors by targeting tumor-associated antigens and redirecting T-cell activity. Tarlatamab, targeting DLL3 in SCLC, demonstrated ...
Researchers at the Medical University of Vienna have taken a closer look at a previously largely unknown component of the ...
Preclinical data support Abalos’ first-in-class approach of safely harnessing the immunostimulatory and anti-tumoral properties of ...
The FDA adds a new boxed warning for immune effector cell-associated enterocolitis with Carvykti, but says the overall ...
Ciltacabtagene autoleucel (cilta-cel; Carvykti) for multiple myeloma has a new boxed warning for immune effector ...
The FDA has adjusted the label of Johnson & Johnson and Legend Biotech’s Carvykti, warning patients and doctors that use of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback